Article
PDE-5 inhibitor use shows no effect on BPH therapy outcomes
On-demand use of a phosphodiesterase type-5 inhibitor did not affect prostatic or urinary outcomes of therapy for BPH, a post hoc analysis of a large randomized trial showed.
Related Videos
Jason Scovell, MD, on clinical utility of IsoPSA across racial groups
Jared S. Winoker, MD, discusses real-world study of CVAC 2.0 for kidney stones
Jim Hu, MD, on urinary continence recovery across RARP techniques
Dean Elterman, MD, shares 3-year data on Zenflow Spring System for BPH
Interpreting PSA Trends in Patients Receiving Darolutamide Plus ADT With mHSPC
Ultra-Low PSA Threshold vs Traditional Thresholds In Clinical Practice
Adoption of New Treatment Modalities to Treat BPH
Safety data on Black patients from ARANOTE
Current Unmet Needs in ccRCC Diagnosis
Decision-Making in Small Renal Masses
Related Content
